Fresenius
German healthcare group headquartered in Bad Homburg, with Fresenius Kabi (pharmaceuticals and clinical nutrition) and Fresenius Helios (private hospitals) as operating companies. FY2025 revenue was 22,554 million euros.
Industry: Healthcare (pharmaceuticals, clinical nutrition and hospital operation) | Location: Bad Homburg, Germany | Founded: 1912
About Fresenius
Fresenius SE & Co. KGaA is a healthcare group whose home page is organised around two businesses. Fresenius Kabi supplies products for patients with chronic or critical illness, while Fresenius Helios is a private hospital operator in Europe. The company also has a services unit, Fresenius Health Services, which supports Helios hospitals internally and external clients; from January 2027 about 1,700 of its more than 4,000 employees are due to move to Helios Kliniken GmbH. Recent news on the site covers an exclusive development agreement with WuXi Biologics to expand a biosimilars pipeline, the acquisition of the remaining 45% of mAbxience for up to 750 million euros, and the sale of Fresenius Medical Care AG shares totalling 13.4 million. The group describes a transformation programme called FutureFresenius, reports third-quarter 2026 financial results, and notes a positive outlook revision from Moody's with a Baa3 rating. It also published an updated Human Rights Statement and received a Building Public Trust Award for sustainability reporting. An investor relations contact is listed.
Leadership
- Michael Sen, Chief Executive Officer and Chairman of the Management Board
- Sara Hennicken, Chief Financial Officer
- Pierluigi Antonelli, Chief Executive Officer, Fresenius Kabi
- Christian Pawlu, Chief Executive Officer, Fresenius Helios
- Michael Moser, Member of the Management Board (legal, compliance, risk, sustainability, human resources and Vamed transformation)
- Wolfgang Kirsch, Chairman of the Supervisory Board
- Michael Diekmann, Deputy Chairman of the Supervisory Board
- Grit Genster, Deputy Chair of the Supervisory Board